{"gene":"TNFRSF10A","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1997,"finding":"DR4 (TRAIL-R1) recruits adaptor proteins FADD, TRADD, and RIP to its cytoplasmic death domain, and DR4-induced apoptosis is blocked by dominant-negative FADD, establishing FADD as a required mediator of DR4-initiated cell death. DR4 also activates NF-κB via a TRADD-dependent pathway.","method":"Co-immunoprecipitation of FADD/TRADD/RIP with DR4; dominant-negative FADD overexpression blocking apoptosis; NF-κB reporter assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP and dominant-negative functional rescue replicated independently in two papers (PMID:9430227, PMID:9430228)","pmids":["9430227","9430228"],"is_preprint":false},{"year":1997,"finding":"TRAIL-R1 (DR4) can physically associate with TRAIL-R2 (DR5), suggesting that TRAIL may signal through heteroreceptor complexes.","method":"Co-immunoprecipitation of TRAIL-R1 with TRAIL-R2","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP, replicated in the same paper; independent replication not established","pmids":["9430228"],"is_preprint":false},{"year":1998,"finding":"Dominant-negative FADD (GFP-ΔF ADD) stably expressed in HeLa cells inhibits TRAIL-R/Apo2-induced cell death, confirming that FADD is an obligatory component of DR4 (TRAIL-R1) apoptotic signaling.","method":"Stable expression of GFP-tagged dominant-negative FADD in HeLa cells; cell death assays","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic loss-of-function with defined cellular apoptosis phenotype, corroborating prior reciprocal Co-IP data","pmids":["9427646"],"is_preprint":false},{"year":2001,"finding":"DR4 (TRAIL-R1) expression is induced by DNA-damaging agents (ionizing radiation, chemotherapeutics) predominantly in cells harboring wild-type p53; introduction of exogenous wild-type p53 up-regulates endogenous DR4, and inhibition of p53 (via HPV E6) suppresses DR4 induction, establishing DR4 as a DNA damage-inducible, p53-regulated gene.","method":"RT-PCR and Western blot in irradiated/drug-treated cells; adenoviral p53 introduction; HPV E6 transfection; transcription inhibitor (actinomycin D) blocking induction","journal":"Journal of cellular physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal genetic manipulations (p53 gain- and loss-of-function) with consistent DR4 expression readouts in single study","pmids":["11382926"],"is_preprint":false},{"year":2005,"finding":"Apo2L/TRAIL activates IKK, JNK, and p38 kinase pathways by assembling a secondary signaling complex downstream of the primary DISC. This secondary complex retains DISC components FADD and caspase-8 but additionally recruits RIP1, TRAF2, and NEMO/IKKγ. Secondary complex formation requires FADD and caspase-8 activity; JNK/p38 activation requires RIP1 and TRAF2; IKK activation requires NEMO.","method":"Co-immunoprecipitation of secondary complex components; siRNA knockdowns of RIP1, TRAF2, NEMO; dominant-negative constructs; kinase activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, siRNA, dominant-negatives) identifying distinct complex components with specific functional readouts","pmids":["16227629"],"is_preprint":false},{"year":2006,"finding":"DR4 undergoes S-palmitoylation on its cytoplasmic domain, which is required for its localization to lipid rafts and its ability to oligomerize; DR5 and TNFR1 are not palmitoylated. Palmitoylation of DR4 is necessary for efficient TRAIL-induced death signal transmission.","method":"Palmitoylation assay (acyl-RAC or equivalent); lipid raft fractionation; oligomerization assays; comparison with DR5 and TNFR1","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biochemical detection of palmitoylation with functional consequence (raft localization, oligomerization, cell death) in single rigorous study","pmids":["19090789"],"is_preprint":false},{"year":2006,"finding":"DR4 is S-nitrosylated at cysteine C336 in its cytoplasmic domain following treatment with nitrosylcobalamin (NO-Cbl). C336A point mutation abolishes S-nitrosylation, reduces caspase-8 activation, and confers resistance to NO-Cbl- and TRAIL-induced apoptosis, identifying C336 as a functionally critical residue for death signaling.","method":"Biotin-switch assay for S-nitrosylation; site-directed mutagenesis of all seven cytoplasmic cysteines to alanine; caspase-8 activity assays; cell viability assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted S-nitrosylation biochemically, validated by systematic mutagenesis of all cytoplasmic cysteines with functional apoptosis readouts","pmids":["16847314"],"is_preprint":false},{"year":2008,"finding":"NF-κB transcriptionally regulates DR4 expression in response to etoposide. The p65 subunit of NF-κB binds a functional NF-κB site in the DR4 promoter; mutation of this site abrogates luciferase induction; p65 knockdown by RNAi blocks etoposide-induced DR4 upregulation; MEKK1 kinase activity is required upstream of NF-κB for DR4 induction.","method":"Luciferase promoter reporter assays with NF-κB site mutation; EMSA; chromatin immunoprecipitation (ChIP); RNAi knockdown of p65; kinase-inactive MEKK1 expression","journal":"Apoptosis : an international journal on programmed cell death","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ChIP, EMSA, reporter mutagenesis, RNAi) in single study demonstrating direct NF-κB binding and functional regulation of DR4 promoter","pmids":["18421578"],"is_preprint":false},{"year":2008,"finding":"ARAP1 (an Arf/Rho GAP adapter protein) physically interacts with the intracellular portion (ICP) of DR4, co-localizes with DR4 in the ER/Golgi, plasma membrane, and early endosomes, and its knockdown reduces DR4 cell-surface levels and slows TRAIL-induced apoptosis, indicating ARAP1 regulates DR4 trafficking to the plasma membrane.","method":"Yeast two-hybrid screen with DR4-ICP; Co-immunoprecipitation of transfected ARAP1 with DR4; co-localization by confocal microscopy; siRNA knockdown with flow cytometry and cell death assays","journal":"Apoptosis : an international journal on programmed cell death","confidence":"High","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid identification, confirmed by Co-IP and co-localization; functional KD showing reduced surface DR4 and attenuated apoptosis","pmids":["18165900"],"is_preprint":false},{"year":2015,"finding":"DDIT3 (CHOP) interacts with phospho-JUN, and the DDIT3·phospho-JUN complex binds the AP-1 site (−304/−298) in the TNFRSF10A (DR4) promoter to drive expression. KAT2A physically interacts with the N-terminal region (aa 1–26) of DDIT3 and participates in a KAT2A·DDIT3·phospho-JUN complex that acetylates H3K9/K14, cooperatively upregulating DR4 during ER stress-mediated apoptosis.","method":"Co-immunoprecipitation; ChIP; luciferase promoter reporter assays with AP-1 site mutation; siRNA knockdown of KAT2A; Western blot for H3K9/K14 acetylation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, ChIP, reporter mutagenesis, RNAi) establishing complex composition and histone modification at TNFRSF10A promoter","pmids":["25770212"],"is_preprint":false},{"year":2010,"finding":"The transcription factor GLI3 binds the DR4 promoter and mediates Hedgehog pathway repression of DR4 expression. siRNA knockdown of GLI3 (but not GLI1 or GLI2) restores DR4 expression and TRAIL sensitivity in cholangiocarcinoma cells; DR4 knockdown mimics Hh-mediated TRAIL resistance.","method":"Luciferase promoter reporter assay; ChIP; siRNA knockdown of GLI1, GLI2, GLI3; DR4 siRNA knockdown; cell death assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct promoter binding by ChIP, confirmed by reporter assay, with gain- and loss-of-function genetic validation showing DR4-dependent phenotype","pmids":["20562908"],"is_preprint":false},{"year":2012,"finding":"p53-dependent activation of the DR4 death receptor pathway, followed by caspase-8-mediated cleavage of BID, and BID-dependent activation of mitochondria-poised BAX, is a key determinant driving cells toward apoptosis versus proliferation arrest after p53 activation by genotoxic stress.","method":"Genetic epistasis using isogenic cell lines; siRNA knockdown of DR4; caspase-8 inhibition; BID cleavage assays; cytochrome C release assays; caspase activation assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods with epistasis analysis placing DR4 specifically upstream of caspase-8/BID/BAX in p53-driven apoptosis","pmids":["22246181"],"is_preprint":false},{"year":2017,"finding":"N-linked glycosylation of TRAIL-R1 (DR4) promotes TRAIL-induced apoptosis: N-glycosylation-defective DR4 mutants show reduced TRAIL receptor aggregation and reduced DISC formation without affecting TRAIL-binding affinity. Additionally, N-glycosylation of DR4 reduces its binding affinity for the CMV immune evasion protein UL141.","method":"Site-directed mutagenesis of N-glycosylation sites; DISC immunoprecipitation; TRAIL-binding affinity assays; UL141 binding assays; apoptosis assays with N-glyc-deficient mutants","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis with reconstitution-level mechanistic dissection of DISC formation and ligand binding; multiple functional readouts","pmids":["28186505"],"is_preprint":false},{"year":2017,"finding":"Using TALEN-based gene editing, TRAIL-R1 (DR4) was shown to be the primary mediator of TRAIL-induced apoptosis in tested tumor cell lines. DR4 also mediates apoptosis during ER stress (co-immunoprecipitating with FADD and caspase-8 upon ER stress induction); however, unlike TRAIL-R2, DR4 is unable to trigger cell migration because it cannot induce calcium flux.","method":"TALEN gene editing to generate isogenic DR4/DR5 knockout cells; Co-immunoprecipitation of DR4 with FADD/caspase-8 during ER stress; calcium flux assays; apoptosis assays with thapsigargin/tunicamycin/brefeldin A; motility/invasion assays","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic gene-edited cell lines with multiple orthogonal functional assays clearly distinguishing DR4 and DR5 roles","pmids":["28039489"],"is_preprint":false},{"year":2000,"finding":"Homozygous deletion of DR4 encompassing its death domain in the FaDu nasopharyngeal cancer cell line confers TRAIL resistance; reintroduction of wild-type DR4 restores TRAIL sensitivity and induces apoptosis, demonstrating that the DR4 death domain is required for TRAIL-induced apoptotic signaling.","method":"Loss-of-heterozygosity/genomic deletion analysis; wild-type DR4 reconstitution by transfection; TRAIL cytotoxicity assays","journal":"International journal of oncology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — natural deletion plus rescue experiment directly linking DR4 death domain loss to TRAIL resistance","pmids":["10762627"],"is_preprint":false},{"year":2021,"finding":"DR4 undergoes constitutive clathrin-dependent and -independent endocytosis and recycling back to the plasma membrane independently of TRAIL sensitivity. Inhibition of endocytosis (with sucrose) sensitizes resistant cells to TRAIL and increases cytotoxicity in sensitive cells, indicating that endocytosis negatively regulates TRAIL-DR4 surface signaling.","method":"Live-cell flow cytometry tracking receptor internalization and recycling; receptor-selective TRAIL variant (DR5-B) to show DR5 internalizes independently of DR4; cycloheximide/brefeldin A to distinguish new synthesis from recycling; sucrose-mediated endocytosis inhibition with TRAIL cytotoxicity readout","journal":"Frontiers in cell and developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal pharmacological and biochemical approaches dissecting DR4 trafficking with functional death assay consequence","pmids":["34660590"],"is_preprint":false},{"year":2011,"finding":"DR4 and DR5 redistribution into lipid rafts upon TRAIL treatment occurs in TRAIL-sensitive (H460) but not in TRAIL-resistant (A549) NSCLC cells; DR4 total expression level does not correlate with TRAIL sensitivity. Lipid raft disruption with nystatin abolishes sensitivity, and DR4 siRNA knockdown in sensitive cells does not affect TRAIL-induced apoptosis capacity, implicating that raft-localized DR4/DR5 rather than total DR4 expression drives sensitivity.","method":"Sucrose density gradient fractionation of lipid rafts; siRNA knockdown of DR4; nystatin treatment; TRAIL apoptosis assays","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — lipid raft fractionation plus siRNA in single lab, single study; negative DR4 siRNA result is informative","pmids":["21769428"],"is_preprint":false},{"year":2012,"finding":"DR4 and DR5 mediate oligomeric Aβ-induced extrinsic apoptosis in human cerebral microvascular endothelial cells: oligomeric Aβ directly binds DR4 and DR5 chimeric fusion proteins, upregulates their expression, and RNA silencing of both receptors protects against Aβ-induced caspase-8 and caspase-9 activation and Bid cleavage.","method":"Direct binding assay using receptor chimeras; RNA silencing of DR4 and DR5; caspase-8/9 activation assays; Bid cleavage assay; immunofluorescence co-localization","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ligand-binding assay and siRNA knockdown with multiple mechanistic readouts in single study","pmids":["22695614"],"is_preprint":false},{"year":2009,"finding":"Valproic acid (a histone deacetylase inhibitor) causes redistribution of DR4 into plasma membrane lipid rafts in U266 myeloma cells, restoring DR4 signaling and overcoming TRAIL resistance; membrane expression level of DR4 (not total expression) and caspase-8 expression levels, but not Mcl-1 intracellular levels, predict myeloma cell sensitivity to TRAIL.","method":"Lipid raft fractionation; flow cytometry for membrane DR4; siRNA for caspase-8 and DR4/DR5; Mcl-1 overexpression; TRAIL apoptosis assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — lipid raft fractionation and multiple siRNA knockdowns in a single study establishing membrane DR4 as the functional determinant","pmids":["17462628"],"is_preprint":false},{"year":2005,"finding":"Epigenetic silencing of DR4 via promoter hypermethylation underlies TRAIL resistance in ovarian cancer cells; demethylation with 5-aza-2'-deoxycytidine or transient DR4 transfection restores TRAIL sensitivity in the TRAIL-resistant A2780 cell line.","method":"Methylation-specific PCR; 5-aza-2'-deoxycytidine demethylation treatment; transient DR4 transfection; TRAIL apoptosis assays","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — demethylation and DR4 reconstitution experiments with functional TRAIL sensitivity readout; single lab","pmids":["15972852"],"is_preprint":false}],"current_model":"TNFRSF10A/DR4 is a cell-surface death receptor that, upon binding of TRAIL/Apo2L, recruits FADD, TRADD, RIP1, and caspase-8 into a death-inducing signaling complex (DISC) to initiate caspase-8-dependent apoptosis; DR4 can also assemble a secondary complex with RIP1, TRAF2, and NEMO to activate NF-κB, JNK, and p38 kinase pathways. DR4 signaling competence is regulated post-translationally by S-palmitoylation (required for lipid raft localization and oligomerization) and N-linked glycosylation (promoting DISC assembly), as well as by S-nitrosylation at C336 (enhancing apoptotic signaling), and by intracellular trafficking controlled by the adaptor ARAP1. DR4 transcription is induced by DNA damage in a p53-dependent manner, and also activated by NF-κB (via MEKK1), by a DDIT3·phospho-JUN·KAT2A complex at its AP-1 promoter element, and repressed by the Hedgehog effector GLI3; promoter hypermethylation silences DR4 in some cancers to confer TRAIL resistance."},"narrative":{"mechanistic_narrative":"TNFRSF10A (DR4/TRAIL-R1) is a cell-surface death receptor that initiates extrinsic apoptosis upon engagement by TRAIL/Apo2L, and is the primary mediator of TRAIL-induced cell death in tumor cells [PMID:28039489]. Through its cytoplasmic death domain, DR4 recruits the adaptor FADD (along with TRADD and RIP), assembling a death-inducing signaling complex in which FADD is an obligatory mediator of apoptosis [PMID:9430227, PMID:9430228, PMID:9427646, PMID:10762627]. Ligand engagement also nucleates a secondary complex retaining FADD and caspase-8 but additionally recruiting RIP1, TRAF2, and NEMO/IKKγ, thereby activating IKK/NF-κB, JNK, and p38 kinase pathways [PMID:16227629]. DR4-driven caspase-8 activity cleaves BID to engage mitochondrial BAX, linking the receptor to the intrinsic apoptotic machinery during p53-driven genotoxic stress responses [PMID:22246181]. DR4 signaling competence is set post-translationally: S-palmitoylation of its cytoplasmic domain drives lipid-raft localization and oligomerization [PMID:19090789], N-linked glycosylation promotes receptor aggregation and DISC formation [PMID:28186505], and S-nitrosylation at C336 enhances caspase-8 activation [PMID:16847314]; surface availability is further governed by ARAP1-dependent trafficking to the plasma membrane [PMID:18165900] and by constitutive endocytosis and recycling that negatively regulate surface signaling [PMID:34660590]. DR4 transcription is induced by DNA damage in a p53-dependent manner [PMID:11382926], by NF-κB/p65 via MEKK1 [PMID:18421578], and by a KAT2A·DDIT3·phospho-JUN complex acting at an AP-1 promoter element during ER stress [PMID:25770212], while it is repressed by the Hedgehog effector GLI3 and silenced by promoter hypermethylation to confer TRAIL resistance in cancer [PMID:20562908, PMID:15972852].","teleology":[{"year":1997,"claim":"Established the core proximal signaling machinery of DR4 by identifying the death-domain adaptors that transduce its apoptotic and NF-κB signals.","evidence":"Co-IP of FADD/TRADD/RIP with DR4 and dominant-negative FADD blocking apoptosis; NF-κB reporter assays","pmids":["9430227","9430228"],"confidence":"High","gaps":["Stoichiometry and order of adaptor assembly not resolved","Did not distinguish DISC from secondary complex"]},{"year":1997,"claim":"Raised the possibility that TRAIL signals through mixed receptor complexes by showing DR4 can associate with DR5.","evidence":"Co-IP of TRAIL-R1 with TRAIL-R2","pmids":["9430228"],"confidence":"Medium","gaps":["Single Co-IP without reciprocal independent validation","Functional significance of heterocomplex unproven"]},{"year":1998,"claim":"Confirmed FADD as an obligatory component of DR4 apoptosis using a clean cellular loss-of-function approach.","evidence":"Stable dominant-negative GFP-FADD expression in HeLa cells with cell death assays","pmids":["9427646"],"confidence":"High","gaps":["Dominant-negative may affect other death receptors","Did not address downstream caspase cascade specifics"]},{"year":2000,"claim":"Demonstrated that the DR4 death domain is genetically required for TRAIL-induced apoptosis via a natural deletion and rescue.","evidence":"Genomic deletion analysis in FaDu cells plus wild-type DR4 reconstitution and TRAIL cytotoxicity","pmids":["10762627"],"confidence":"High","gaps":["Single cell-line context","Does not separate DR4 contribution from DR5 in other settings"]},{"year":2001,"claim":"Placed DR4 in the DNA-damage response by establishing it as a p53-inducible gene, connecting genotoxic stress to extrinsic apoptosis.","evidence":"RT-PCR/Western in irradiated and drug-treated cells with adenoviral p53 gain- and HPV E6 loss-of-function","pmids":["11382926"],"confidence":"High","gaps":["Direct p53 binding site not mapped here","Whether induction is sufficient for apoptosis not addressed"]},{"year":2005,"claim":"Identified promoter hypermethylation as an epigenetic mechanism that silences DR4 and confers TRAIL resistance.","evidence":"Methylation-specific PCR, 5-aza-2'-deoxycytidine demethylation, and DR4 reconstitution in ovarian cancer cells","pmids":["15972852"],"confidence":"Medium","gaps":["Single lab/cell line","Demethylation effects not gene-specific"]},{"year":2005,"claim":"Defined how DR4 activates kinase pathways by resolving a secondary signaling complex distinct from the DISC.","evidence":"Co-IP of secondary complex, siRNA of RIP1/TRAF2/NEMO, dominant-negatives, and kinase assays","pmids":["16227629"],"confidence":"High","gaps":["Spatial/temporal relationship to primary DISC not fully resolved","Physiological outcome of NF-κB/JNK/p38 activation context-dependent"]},{"year":2006,"claim":"Revealed S-palmitoylation as a DR4-specific lipid modification required for raft localization and oligomerization, distinguishing it from DR5 and TNFR1.","evidence":"Palmitoylation assay, raft fractionation, oligomerization assays, comparison with DR5/TNFR1","pmids":["19090789"],"confidence":"High","gaps":["Palmitoyltransferase responsible not identified","Dynamics/reversibility of palmitoylation unaddressed"]},{"year":2006,"claim":"Identified C336 S-nitrosylation as a functionally critical redox modification enhancing DR4 death signaling.","evidence":"Biotin-switch assay, systematic mutagenesis of all cytoplasmic cysteines, caspase-8 and viability assays","pmids":["16847314"],"confidence":"High","gaps":["Endogenous NO source/enzyme not defined","Structural basis of how nitrosylation enhances signaling unknown"]},{"year":2008,"claim":"Showed direct NF-κB/p65 transcriptional control of DR4 downstream of MEKK1, adding a second stress-responsive induction route.","evidence":"Promoter reporter with site mutation, EMSA, ChIP, p65 RNAi, kinase-inactive MEKK1","pmids":["18421578"],"confidence":"High","gaps":["Crosstalk with p53-driven induction not resolved","Conditions favoring NF-κB vs p53 control unclear"]},{"year":2008,"claim":"Identified ARAP1 as a trafficking adaptor controlling DR4 delivery to the cell surface, linking receptor abundance at the membrane to apoptotic competence.","evidence":"Yeast two-hybrid with DR4-ICP, Co-IP, confocal co-localization, siRNA with flow cytometry and death assays","pmids":["18165900"],"confidence":"High","gaps":["GAP catalytic role in trafficking not dissected","Direct vs indirect interaction not fully established"]},{"year":2010,"claim":"Demonstrated Hedgehog-mediated repression of DR4 through GLI3 binding, explaining a transcriptional route to TRAIL resistance.","evidence":"Promoter reporter, ChIP, GLI1/2/3 and DR4 siRNA, death assays in cholangiocarcinoma","pmids":["20562908"],"confidence":"High","gaps":["GLI3 repressor cofactors not identified","Generality beyond cholangiocarcinoma untested"]},{"year":2011,"claim":"Showed that raft-localized rather than total DR4 determines TRAIL sensitivity, refining the receptor-availability model.","evidence":"Sucrose-gradient raft fractionation, DR4 siRNA, nystatin disruption, apoptosis assays in NSCLC lines","pmids":["21769428"],"confidence":"Medium","gaps":["Single-study two-cell-line comparison","Molecular trigger of raft redistribution not defined"]},{"year":2012,"claim":"Placed DR4 mechanistically within the p53 apoptosis decision, upstream of caspase-8/BID/BAX, linking extrinsic and intrinsic pathways.","evidence":"Isogenic epistasis, DR4 siRNA, caspase-8 inhibition, BID cleavage and cytochrome C release assays","pmids":["22246181"],"confidence":"High","gaps":["Relative contribution of DR4 vs DR5 in p53 response not separated","Determinants of apoptosis vs arrest choice partly unresolved"]},{"year":2012,"claim":"Extended DR4 ligand biology beyond TRAIL by showing oligomeric Aβ binds DR4 to drive endothelial apoptosis.","evidence":"Receptor chimera binding, DR4/DR5 RNA silencing, caspase-8/9 and Bid cleavage assays","pmids":["22695614"],"confidence":"Medium","gaps":["Single-study system (cerebral endothelial cells)","Physiological relevance and binding site not mapped"]},{"year":2015,"claim":"Defined an ER-stress transcriptional module (KAT2A·DDIT3·phospho-JUN) that activates DR4 via histone acetylation at an AP-1 promoter element.","evidence":"Co-IP, ChIP, AP-1 site reporter mutagenesis, KAT2A siRNA, H3K9/K14 acetylation Western","pmids":["25770212"],"confidence":"High","gaps":["Integration with NF-κB and p53 inputs unresolved","Stimulus specificity of complex assembly unclear"]},{"year":2017,"claim":"Established DR4 as the primary TRAIL apoptosis mediator and a participant in ER-stress apoptosis, while distinguishing it from DR5 in being unable to drive migratory calcium signaling.","evidence":"TALEN-edited isogenic DR4/DR5 knockouts, Co-IP with FADD/caspase-8 under ER stress, calcium flux and motility assays","pmids":["28039489"],"confidence":"High","gaps":["Mechanism for DR4's inability to flux calcium not defined","Cell-line dependence of receptor dominance"]},{"year":2017,"claim":"Showed N-linked glycosylation promotes DR4 aggregation and DISC formation and modulates viral immune evasion, defining a glycan-level control of signaling.","evidence":"Glycosylation-site mutagenesis, DISC IP, TRAIL- and UL141-binding assays, apoptosis readouts","pmids":["28186505"],"confidence":"High","gaps":["Specific glycan structures involved not characterized","In vivo relevance of UL141 modulation untested"]},{"year":2021,"claim":"Demonstrated that constitutive endocytosis and recycling of DR4 negatively regulate surface TRAIL signaling, providing a dynamic control of receptor availability.","evidence":"Live-cell flow cytometry of internalization/recycling, receptor-selective TRAIL variant, brefeldin A/cycloheximide, sucrose endocytosis inhibition with cytotoxicity","pmids":["34660590"],"confidence":"High","gaps":["Adaptors/machinery selecting clathrin-dependent vs independent routes unidentified","Signaling status of internalized receptor unknown"]},{"year":null,"claim":"How the multiple post-translational modifications, trafficking routes, and competing transcriptional inputs are integrated to set DR4 surface density and signaling competence in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking palmitoylation, glycosylation, nitrosylation, ARAP1 trafficking, and endocytosis","Enzymes catalyzing palmitoylation and physiological NO-donor unknown","Hierarchy of p53, NF-κB, DDIT3/AP-1, and GLI3 transcriptional control not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,13,14]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,11]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,8,15,16]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[8,15]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[8]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,2,11,13,14]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[9,13]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,7,9,10]}],"complexes":["DISC (death-inducing signaling complex)","TRAIL secondary signaling complex (FADD/caspase-8/RIP1/TRAF2/NEMO)","KAT2A·DDIT3·phospho-JUN promoter complex"],"partners":["FADD","TRADD","RIP1","TRAF2","NEMO","TNFRSF10B","ARAP1","CASP8"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00220","full_name":"Tumor necrosis factor receptor superfamily member 10A","aliases":["Death receptor 4","TNF-related apoptosis-inducing ligand receptor 1","TRAIL receptor 1","TRAIL-R1"],"length_aa":468,"mass_kda":50.1,"function":"Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:26457518, PubMed:38532423). The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis (PubMed:19090789). Promotes the activation of NF-kappa-B (PubMed:9430227)","subcellular_location":"Cell membrane; Membrane raft; Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/O00220/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF10A","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF10A","total_profiled":1310},"omim":[{"mim_id":"619856","title":"ANKYRIN REPEAT DOMAIN-CONTAINING PROTEIN 50; ANKRD50","url":"https://www.omim.org/entry/619856"},{"mim_id":"615741","title":"DAP3-BINDING CELL DEATH ENHANCER 1; DELE1","url":"https://www.omim.org/entry/615741"},{"mim_id":"606992","title":"INOSITOL HEXAPHOSPHATE KINASE 2; IP6K2","url":"https://www.omim.org/entry/606992"},{"mim_id":"603611","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 10A; TNFRSF10A","url":"https://www.omim.org/entry/603611"},{"mim_id":"603075","title":"MACULAR DEGENERATION, AGE-RELATED, 1; ARMD1","url":"https://www.omim.org/entry/603075"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFRSF10A"},"hgnc":{"alias_symbol":["DR4","Apo2","TRAILR-1","CD261","TRAILR1"],"prev_symbol":[]},"alphafold":{"accession":"O00220","domains":[{"cath_id":"2.10.50.10","chopping":"130-191","consensus_level":"medium","plddt":93.6613,"start":130,"end":191},{"cath_id":"2.10.50.10","chopping":"193-235","consensus_level":"medium","plddt":89.2302,"start":193,"end":235},{"cath_id":"1.10.533.10","chopping":"353-457","consensus_level":"high","plddt":88.4178,"start":353,"end":457}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00220","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00220-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00220-F1-predicted_aligned_error_v6.png","plddt_mean":66.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF10A","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF10A"},"sequence":{"accession":"O00220","fasta_url":"https://rest.uniprot.org/uniprotkb/O00220.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00220/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00220"}},"corpus_meta":[{"pmid":"10411544","id":"PMC_10411544","title":"Safety and antitumor activity of recombinant soluble Apo2 ligand.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10411544","citation_count":1917,"is_preprint":false},{"pmid":"9430227","id":"PMC_9430227","title":"Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9430227","citation_count":605,"is_preprint":false},{"pmid":"9430228","id":"PMC_9430228","title":"TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9430228","citation_count":598,"is_preprint":false},{"pmid":"3458223","id":"PMC_3458223","title":"Molecular diversity of HLA-DR4 haplotypes.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3458223","citation_count":391,"is_preprint":false},{"pmid":"1944595","id":"PMC_1944595","title":"Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility.","date":"1991","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1944595","citation_count":362,"is_preprint":false},{"pmid":"15208660","id":"PMC_15208660","title":"Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15208660","citation_count":241,"is_preprint":false},{"pmid":"16227629","id":"PMC_16227629","title":"Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16227629","citation_count":227,"is_preprint":false},{"pmid":"11739488","id":"PMC_11739488","title":"Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11739488","citation_count":214,"is_preprint":false},{"pmid":"10415024","id":"PMC_10415024","title":"Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10415024","citation_count":210,"is_preprint":false},{"pmid":"8137825","id":"PMC_8137825","title":"Dimerization interfaces formed between the DNA binding domains determine the cooperative binding of RXR/RAR and RXR/TR heterodimers to DR5 and DR4 elements.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8137825","citation_count":183,"is_preprint":false},{"pmid":"9613612","id":"PMC_9613612","title":"APO2 ligand: a novel lethal weapon against malignant glioma?","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9613612","citation_count":167,"is_preprint":false},{"pmid":"9754559","id":"PMC_9754559","title":"Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9754559","citation_count":167,"is_preprint":false},{"pmid":"9427646","id":"PMC_9427646","title":"Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction.","date":"1998","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9427646","citation_count":142,"is_preprint":false},{"pmid":"15014077","id":"PMC_15014077","title":"The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis and is regulated by a DR4 element.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15014077","citation_count":137,"is_preprint":false},{"pmid":"1345171","id":"PMC_1345171","title":"Insulin gene region-encoded susceptibility to type 1 diabetes is not restricted to HLA-DR4-positive individuals.","date":"1992","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1345171","citation_count":123,"is_preprint":false},{"pmid":"20813513","id":"PMC_20813513","title":"Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation.","date":"2010","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20813513","citation_count":121,"is_preprint":false},{"pmid":"15972852","id":"PMC_15972852","title":"Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.","date":"2005","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/15972852","citation_count":117,"is_preprint":false},{"pmid":"10562307","id":"PMC_10562307","title":"Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10562307","citation_count":115,"is_preprint":false},{"pmid":"11059770","id":"PMC_11059770","title":"Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11059770","citation_count":113,"is_preprint":false},{"pmid":"9415413","id":"PMC_9415413","title":"Monitoring early cellular responses in apoptosis is aided by the mitochondrial membrane protein-specific monoclonal antibody APO2.7.","date":"1997","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/9415413","citation_count":112,"is_preprint":false},{"pmid":"11382926","id":"PMC_11382926","title":"Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene.","date":"2001","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11382926","citation_count":110,"is_preprint":false},{"pmid":"10706675","id":"PMC_10706675","title":"TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10706675","citation_count":108,"is_preprint":false},{"pmid":"25770212","id":"PMC_25770212","title":"DDIT3 and KAT2A Proteins Regulate TNFRSF10A and TNFRSF10B Expression in Endoplasmic Reticulum Stress-mediated Apoptosis in Human Lung Cancer Cells.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25770212","citation_count":96,"is_preprint":false},{"pmid":"27752089","id":"PMC_27752089","title":"Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27752089","citation_count":96,"is_preprint":false},{"pmid":"10762627","id":"PMC_10762627","title":"Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance.","date":"2000","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10762627","citation_count":95,"is_preprint":false},{"pmid":"12154014","id":"PMC_12154014","title":"Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12154014","citation_count":93,"is_preprint":false},{"pmid":"10736093","id":"PMC_10736093","title":"Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages.","date":"2000","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10736093","citation_count":82,"is_preprint":false},{"pmid":"9520453","id":"PMC_9520453","title":"T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520453","citation_count":82,"is_preprint":false},{"pmid":"3261186","id":"PMC_3261186","title":"HLA-DR4 and other genetic markers in rheumatoid arthritis.","date":"1988","source":"British journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/3261186","citation_count":82,"is_preprint":false},{"pmid":"28186505","id":"PMC_28186505","title":"N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.","date":"2017","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/28186505","citation_count":79,"is_preprint":false},{"pmid":"19090789","id":"PMC_19090789","title":"Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19090789","citation_count":76,"is_preprint":false},{"pmid":"12097388","id":"PMC_12097388","title":"IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12097388","citation_count":76,"is_preprint":false},{"pmid":"9990333","id":"PMC_9990333","title":"Expression of Fas-Fas ligand antigens and apoptotic marker APO2.7 by the human conjunctival epithelium. Positive correlation with class II HLA DR expression in inflammatory ocular surface disorders.","date":"1998","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/9990333","citation_count":74,"is_preprint":false},{"pmid":"27865080","id":"PMC_27865080","title":"Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2.","date":"2016","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/27865080","citation_count":73,"is_preprint":false},{"pmid":"22695614","id":"PMC_22695614","title":"TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer's Aβ.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22695614","citation_count":73,"is_preprint":false},{"pmid":"33693937","id":"PMC_33693937","title":"The LARGE2-APO1/APO2 regulatory module controls panicle size and grain number in rice.","date":"2021","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/33693937","citation_count":69,"is_preprint":false},{"pmid":"17881904","id":"PMC_17881904","title":"Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4.","date":"2007","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17881904","citation_count":69,"is_preprint":false},{"pmid":"9121744","id":"PMC_9121744","title":"Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California.","date":"1995","source":"Ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/9121744","citation_count":67,"is_preprint":false},{"pmid":"31548531","id":"PMC_31548531","title":"Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.","date":"2017","source":"Antibodies (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31548531","citation_count":66,"is_preprint":false},{"pmid":"15604280","id":"PMC_15604280","title":"Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15604280","citation_count":66,"is_preprint":false},{"pmid":"11095979","id":"PMC_11095979","title":"Genomic organization and transcriptional regulation of human Apo2/TRAIL gene.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11095979","citation_count":65,"is_preprint":false},{"pmid":"28039489","id":"PMC_28039489","title":"TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28039489","citation_count":65,"is_preprint":false},{"pmid":"16847314","id":"PMC_16847314","title":"Nitrosylcobalamin promotes cell death via S nitrosylation of Apo2L/TRAIL receptor DR4.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16847314","citation_count":63,"is_preprint":false},{"pmid":"22738917","id":"PMC_22738917","title":"Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.","date":"2012","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22738917","citation_count":61,"is_preprint":false},{"pmid":"19617574","id":"PMC_19617574","title":"Cross-recognition of HLA DR4 alloantigen by virus-specific CD8+ T cells: a new paradigm for self-/nonself-recognition.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19617574","citation_count":59,"is_preprint":false},{"pmid":"16638930","id":"PMC_16638930","title":"Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16638930","citation_count":57,"is_preprint":false},{"pmid":"12097384","id":"PMC_12097384","title":"Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12097384","citation_count":56,"is_preprint":false},{"pmid":"22480748","id":"PMC_22480748","title":"Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.","date":"2012","source":"Joint bone spine","url":"https://pubmed.ncbi.nlm.nih.gov/22480748","citation_count":55,"is_preprint":false},{"pmid":"26708505","id":"PMC_26708505","title":"Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/26708505","citation_count":54,"is_preprint":false},{"pmid":"8601742","id":"PMC_8601742","title":"HLA-DR4 may determine expression of actinic prurigo in British patients.","date":"1996","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8601742","citation_count":54,"is_preprint":false},{"pmid":"19487610","id":"PMC_19487610","title":"HLA-DR4 as a risk allele for autism acting in mothers of probands possibly during pregnancy.","date":"2009","source":"Archives of pediatrics & adolescent medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19487610","citation_count":54,"is_preprint":false},{"pmid":"29899551","id":"PMC_29899551","title":"Proscillaridin A induces apoptosis and suppresses non-small-cell lung cancer tumor growth via calcium-induced DR4 upregulation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29899551","citation_count":53,"is_preprint":false},{"pmid":"22672670","id":"PMC_22672670","title":"MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma.","date":"2012","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22672670","citation_count":52,"is_preprint":false},{"pmid":"10677278","id":"PMC_10677278","title":"Ligand-triggered stabilization of vitamin D receptor/retinoid X receptor heterodimer conformations on DR4-type response elements.","date":"2000","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10677278","citation_count":52,"is_preprint":false},{"pmid":"17462628","id":"PMC_17462628","title":"Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.","date":"2007","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/17462628","citation_count":51,"is_preprint":false},{"pmid":"14614459","id":"PMC_14614459","title":"Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14614459","citation_count":50,"is_preprint":false},{"pmid":"16368536","id":"PMC_16368536","title":"APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy.","date":"2006","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/16368536","citation_count":49,"is_preprint":false},{"pmid":"11857340","id":"PMC_11857340","title":"Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11857340","citation_count":49,"is_preprint":false},{"pmid":"18209050","id":"PMC_18209050","title":"Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18209050","citation_count":47,"is_preprint":false},{"pmid":"10486525","id":"PMC_10486525","title":"Expression of mitochondrial Apo2.7 molecules and caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins.","date":"1999","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/10486525","citation_count":47,"is_preprint":false},{"pmid":"20430723","id":"PMC_20430723","title":"TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells.","date":"2009","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/20430723","citation_count":46,"is_preprint":false},{"pmid":"10548878","id":"PMC_10548878","title":"Control of apoptosis signaling by Apo2 ligand.","date":"1999","source":"Recent progress in hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/10548878","citation_count":45,"is_preprint":false},{"pmid":"18421578","id":"PMC_18421578","title":"Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment.","date":"2008","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/18421578","citation_count":44,"is_preprint":false},{"pmid":"20562908","id":"PMC_20562908","title":"GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20562908","citation_count":44,"is_preprint":false},{"pmid":"12375325","id":"PMC_12375325","title":"Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis.","date":"2002","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/12375325","citation_count":42,"is_preprint":false},{"pmid":"2953314","id":"PMC_2953314","title":"HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease.","date":"1987","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/2953314","citation_count":41,"is_preprint":false},{"pmid":"11094433","id":"PMC_11094433","title":"Association of MHC and rheumatoid arthritis. Association of RA with HLA-DR4: the role of repertoire selection.","date":"2000","source":"Arthritis research","url":"https://pubmed.ncbi.nlm.nih.gov/11094433","citation_count":41,"is_preprint":false},{"pmid":"10228045","id":"PMC_10228045","title":"Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10228045","citation_count":40,"is_preprint":false},{"pmid":"12584736","id":"PMC_12584736","title":"Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12584736","citation_count":39,"is_preprint":false},{"pmid":"12851490","id":"PMC_12851490","title":"Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53.","date":"2003","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/12851490","citation_count":38,"is_preprint":false},{"pmid":"19148581","id":"PMC_19148581","title":"Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.","date":"2009","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19148581","citation_count":36,"is_preprint":false},{"pmid":"34660590","id":"PMC_34660590","title":"Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34660590","citation_count":35,"is_preprint":false},{"pmid":"22246181","id":"PMC_22246181","title":"A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX.","date":"2012","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22246181","citation_count":35,"is_preprint":false},{"pmid":"15240697","id":"PMC_15240697","title":"Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15240697","citation_count":35,"is_preprint":false},{"pmid":"33863750","id":"PMC_33863750","title":"The shared susceptibility epitope of HLA-DR4 binds citrullinated self-antigens and the TCR.","date":"2021","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33863750","citation_count":33,"is_preprint":false},{"pmid":"22948392","id":"PMC_22948392","title":"Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.","date":"2012","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/22948392","citation_count":33,"is_preprint":false},{"pmid":"10674967","id":"PMC_10674967","title":"HLA associations in type 1 diabetes among patients not carrying high-risk DR3-DQ2 or DR4-DQ8 haplotypes.","date":"1999","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/10674967","citation_count":33,"is_preprint":false},{"pmid":"19305384","id":"PMC_19305384","title":"Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.","date":"2009","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/19305384","citation_count":32,"is_preprint":false},{"pmid":"12210766","id":"PMC_12210766","title":"Differential nuclear receptor signalling from DR4-type response elements.","date":"2002","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12210766","citation_count":32,"is_preprint":false},{"pmid":"19349211","id":"PMC_19349211","title":"TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects.","date":"2009","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/19349211","citation_count":32,"is_preprint":false},{"pmid":"24481449","id":"PMC_24481449","title":"CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24481449","citation_count":31,"is_preprint":false},{"pmid":"15547696","id":"PMC_15547696","title":"Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15547696","citation_count":31,"is_preprint":false},{"pmid":"31817791","id":"PMC_31817791","title":"Benzyl Isothiocyanate Induces Apoptosis via Reactive Oxygen Species-Initiated Mitochondrial Dysfunction and DR4 and DR5 Death Receptor Activation in Gastric Adenocarcinoma Cells.","date":"2019","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/31817791","citation_count":30,"is_preprint":false},{"pmid":"17431115","id":"PMC_17431115","title":"S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.","date":"2007","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17431115","citation_count":27,"is_preprint":false},{"pmid":"10760796","id":"PMC_10760796","title":"CD59 cross-linking induces secretion of APO2 ligand in overactivated human T cells.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10760796","citation_count":26,"is_preprint":false},{"pmid":"10408913","id":"PMC_10408913","title":"Induction of mitochondrial Apo2.7 molecules and generation of reactive oxygen-intermediates in cultured lymphocytes by the toxic proteins from Viscum album L.","date":"1999","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/10408913","citation_count":26,"is_preprint":false},{"pmid":"22802267","id":"PMC_22802267","title":"Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.","date":"2012","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22802267","citation_count":26,"is_preprint":false},{"pmid":"21769428","id":"PMC_21769428","title":"Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells.","date":"2011","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21769428","citation_count":26,"is_preprint":false},{"pmid":"8651986","id":"PMC_8651986","title":"Synergy between T cell receptor beta gene polymorphism and HLA-DR4 in susceptibility to rheumatoid arthritis.","date":"1996","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/8651986","citation_count":26,"is_preprint":false},{"pmid":"32917855","id":"PMC_32917855","title":"Reduction in MLKL-mediated endosomal trafficking enhances the TRAIL-DR4/5 signal to increase cancer cell death.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32917855","citation_count":25,"is_preprint":false},{"pmid":"18506881","id":"PMC_18506881","title":"HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18506881","citation_count":25,"is_preprint":false},{"pmid":"30302902","id":"PMC_30302902","title":"Short Panicle 3 controls panicle architecture by upregulating APO2/RFL and increasing cytokinin content in rice.","date":"2019","source":"Journal of integrative plant biology","url":"https://pubmed.ncbi.nlm.nih.gov/30302902","citation_count":25,"is_preprint":false},{"pmid":"17949947","id":"PMC_17949947","title":"Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice.","date":"2007","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/17949947","citation_count":24,"is_preprint":false},{"pmid":"12941540","id":"PMC_12941540","title":"Inhibition of T-cell activation with HLA-DR1/DR4 restricted Non-T-cell stimulating peptides.","date":"2003","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12941540","citation_count":24,"is_preprint":false},{"pmid":"25482930","id":"PMC_25482930","title":"DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.","date":"2014","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25482930","citation_count":24,"is_preprint":false},{"pmid":"18165900","id":"PMC_18165900","title":"Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane.","date":"2008","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/18165900","citation_count":23,"is_preprint":false},{"pmid":"9369481","id":"PMC_9369481","title":"The orphan nuclear receptor TR2 suppresses a DR4 hormone response element of the mouse CRABP-I gene promoter.","date":"1997","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9369481","citation_count":22,"is_preprint":false},{"pmid":"30887612","id":"PMC_30887612","title":"Morin enhances auranofin anticancer activity by up-regulation of DR4 and DR5 and modulation of Bcl-2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells.","date":"2019","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/30887612","citation_count":22,"is_preprint":false},{"pmid":"8722074","id":"PMC_8722074","title":"Transcomplementation of HLA DQA1-DQB1 in DR3/DR4 and DR3/DR9 heterozygotes and IDDM in Taiwanese families.","date":"1995","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/8722074","citation_count":22,"is_preprint":false},{"pmid":"19643596","id":"PMC_19643596","title":"TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis.","date":"2009","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/19643596","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52631,"output_tokens":5530,"usd":0.120422,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14028,"output_tokens":5472,"usd":0.10347,"stage2_stop_reason":"end_turn"},"total_usd":0.223892,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"DR4 (TRAIL-R1) recruits adaptor proteins FADD, TRADD, and RIP to its cytoplasmic death domain, and DR4-induced apoptosis is blocked by dominant-negative FADD, establishing FADD as a required mediator of DR4-initiated cell death. DR4 also activates NF-κB via a TRADD-dependent pathway.\",\n      \"method\": \"Co-immunoprecipitation of FADD/TRADD/RIP with DR4; dominant-negative FADD overexpression blocking apoptosis; NF-κB reporter assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP and dominant-negative functional rescue replicated independently in two papers (PMID:9430227, PMID:9430228)\",\n      \"pmids\": [\"9430227\", \"9430228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TRAIL-R1 (DR4) can physically associate with TRAIL-R2 (DR5), suggesting that TRAIL may signal through heteroreceptor complexes.\",\n      \"method\": \"Co-immunoprecipitation of TRAIL-R1 with TRAIL-R2\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP, replicated in the same paper; independent replication not established\",\n      \"pmids\": [\"9430228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Dominant-negative FADD (GFP-ΔF ADD) stably expressed in HeLa cells inhibits TRAIL-R/Apo2-induced cell death, confirming that FADD is an obligatory component of DR4 (TRAIL-R1) apoptotic signaling.\",\n      \"method\": \"Stable expression of GFP-tagged dominant-negative FADD in HeLa cells; cell death assays\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic loss-of-function with defined cellular apoptosis phenotype, corroborating prior reciprocal Co-IP data\",\n      \"pmids\": [\"9427646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"DR4 (TRAIL-R1) expression is induced by DNA-damaging agents (ionizing radiation, chemotherapeutics) predominantly in cells harboring wild-type p53; introduction of exogenous wild-type p53 up-regulates endogenous DR4, and inhibition of p53 (via HPV E6) suppresses DR4 induction, establishing DR4 as a DNA damage-inducible, p53-regulated gene.\",\n      \"method\": \"RT-PCR and Western blot in irradiated/drug-treated cells; adenoviral p53 introduction; HPV E6 transfection; transcription inhibitor (actinomycin D) blocking induction\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal genetic manipulations (p53 gain- and loss-of-function) with consistent DR4 expression readouts in single study\",\n      \"pmids\": [\"11382926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Apo2L/TRAIL activates IKK, JNK, and p38 kinase pathways by assembling a secondary signaling complex downstream of the primary DISC. This secondary complex retains DISC components FADD and caspase-8 but additionally recruits RIP1, TRAF2, and NEMO/IKKγ. Secondary complex formation requires FADD and caspase-8 activity; JNK/p38 activation requires RIP1 and TRAF2; IKK activation requires NEMO.\",\n      \"method\": \"Co-immunoprecipitation of secondary complex components; siRNA knockdowns of RIP1, TRAF2, NEMO; dominant-negative constructs; kinase activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, siRNA, dominant-negatives) identifying distinct complex components with specific functional readouts\",\n      \"pmids\": [\"16227629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"DR4 undergoes S-palmitoylation on its cytoplasmic domain, which is required for its localization to lipid rafts and its ability to oligomerize; DR5 and TNFR1 are not palmitoylated. Palmitoylation of DR4 is necessary for efficient TRAIL-induced death signal transmission.\",\n      \"method\": \"Palmitoylation assay (acyl-RAC or equivalent); lipid raft fractionation; oligomerization assays; comparison with DR5 and TNFR1\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical detection of palmitoylation with functional consequence (raft localization, oligomerization, cell death) in single rigorous study\",\n      \"pmids\": [\"19090789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"DR4 is S-nitrosylated at cysteine C336 in its cytoplasmic domain following treatment with nitrosylcobalamin (NO-Cbl). C336A point mutation abolishes S-nitrosylation, reduces caspase-8 activation, and confers resistance to NO-Cbl- and TRAIL-induced apoptosis, identifying C336 as a functionally critical residue for death signaling.\",\n      \"method\": \"Biotin-switch assay for S-nitrosylation; site-directed mutagenesis of all seven cytoplasmic cysteines to alanine; caspase-8 activity assays; cell viability assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted S-nitrosylation biochemically, validated by systematic mutagenesis of all cytoplasmic cysteines with functional apoptosis readouts\",\n      \"pmids\": [\"16847314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"NF-κB transcriptionally regulates DR4 expression in response to etoposide. The p65 subunit of NF-κB binds a functional NF-κB site in the DR4 promoter; mutation of this site abrogates luciferase induction; p65 knockdown by RNAi blocks etoposide-induced DR4 upregulation; MEKK1 kinase activity is required upstream of NF-κB for DR4 induction.\",\n      \"method\": \"Luciferase promoter reporter assays with NF-κB site mutation; EMSA; chromatin immunoprecipitation (ChIP); RNAi knockdown of p65; kinase-inactive MEKK1 expression\",\n      \"journal\": \"Apoptosis : an international journal on programmed cell death\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ChIP, EMSA, reporter mutagenesis, RNAi) in single study demonstrating direct NF-κB binding and functional regulation of DR4 promoter\",\n      \"pmids\": [\"18421578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ARAP1 (an Arf/Rho GAP adapter protein) physically interacts with the intracellular portion (ICP) of DR4, co-localizes with DR4 in the ER/Golgi, plasma membrane, and early endosomes, and its knockdown reduces DR4 cell-surface levels and slows TRAIL-induced apoptosis, indicating ARAP1 regulates DR4 trafficking to the plasma membrane.\",\n      \"method\": \"Yeast two-hybrid screen with DR4-ICP; Co-immunoprecipitation of transfected ARAP1 with DR4; co-localization by confocal microscopy; siRNA knockdown with flow cytometry and cell death assays\",\n      \"journal\": \"Apoptosis : an international journal on programmed cell death\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid identification, confirmed by Co-IP and co-localization; functional KD showing reduced surface DR4 and attenuated apoptosis\",\n      \"pmids\": [\"18165900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DDIT3 (CHOP) interacts with phospho-JUN, and the DDIT3·phospho-JUN complex binds the AP-1 site (−304/−298) in the TNFRSF10A (DR4) promoter to drive expression. KAT2A physically interacts with the N-terminal region (aa 1–26) of DDIT3 and participates in a KAT2A·DDIT3·phospho-JUN complex that acetylates H3K9/K14, cooperatively upregulating DR4 during ER stress-mediated apoptosis.\",\n      \"method\": \"Co-immunoprecipitation; ChIP; luciferase promoter reporter assays with AP-1 site mutation; siRNA knockdown of KAT2A; Western blot for H3K9/K14 acetylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, ChIP, reporter mutagenesis, RNAi) establishing complex composition and histone modification at TNFRSF10A promoter\",\n      \"pmids\": [\"25770212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The transcription factor GLI3 binds the DR4 promoter and mediates Hedgehog pathway repression of DR4 expression. siRNA knockdown of GLI3 (but not GLI1 or GLI2) restores DR4 expression and TRAIL sensitivity in cholangiocarcinoma cells; DR4 knockdown mimics Hh-mediated TRAIL resistance.\",\n      \"method\": \"Luciferase promoter reporter assay; ChIP; siRNA knockdown of GLI1, GLI2, GLI3; DR4 siRNA knockdown; cell death assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct promoter binding by ChIP, confirmed by reporter assay, with gain- and loss-of-function genetic validation showing DR4-dependent phenotype\",\n      \"pmids\": [\"20562908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"p53-dependent activation of the DR4 death receptor pathway, followed by caspase-8-mediated cleavage of BID, and BID-dependent activation of mitochondria-poised BAX, is a key determinant driving cells toward apoptosis versus proliferation arrest after p53 activation by genotoxic stress.\",\n      \"method\": \"Genetic epistasis using isogenic cell lines; siRNA knockdown of DR4; caspase-8 inhibition; BID cleavage assays; cytochrome C release assays; caspase activation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods with epistasis analysis placing DR4 specifically upstream of caspase-8/BID/BAX in p53-driven apoptosis\",\n      \"pmids\": [\"22246181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"N-linked glycosylation of TRAIL-R1 (DR4) promotes TRAIL-induced apoptosis: N-glycosylation-defective DR4 mutants show reduced TRAIL receptor aggregation and reduced DISC formation without affecting TRAIL-binding affinity. Additionally, N-glycosylation of DR4 reduces its binding affinity for the CMV immune evasion protein UL141.\",\n      \"method\": \"Site-directed mutagenesis of N-glycosylation sites; DISC immunoprecipitation; TRAIL-binding affinity assays; UL141 binding assays; apoptosis assays with N-glyc-deficient mutants\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis with reconstitution-level mechanistic dissection of DISC formation and ligand binding; multiple functional readouts\",\n      \"pmids\": [\"28186505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Using TALEN-based gene editing, TRAIL-R1 (DR4) was shown to be the primary mediator of TRAIL-induced apoptosis in tested tumor cell lines. DR4 also mediates apoptosis during ER stress (co-immunoprecipitating with FADD and caspase-8 upon ER stress induction); however, unlike TRAIL-R2, DR4 is unable to trigger cell migration because it cannot induce calcium flux.\",\n      \"method\": \"TALEN gene editing to generate isogenic DR4/DR5 knockout cells; Co-immunoprecipitation of DR4 with FADD/caspase-8 during ER stress; calcium flux assays; apoptosis assays with thapsigargin/tunicamycin/brefeldin A; motility/invasion assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic gene-edited cell lines with multiple orthogonal functional assays clearly distinguishing DR4 and DR5 roles\",\n      \"pmids\": [\"28039489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Homozygous deletion of DR4 encompassing its death domain in the FaDu nasopharyngeal cancer cell line confers TRAIL resistance; reintroduction of wild-type DR4 restores TRAIL sensitivity and induces apoptosis, demonstrating that the DR4 death domain is required for TRAIL-induced apoptotic signaling.\",\n      \"method\": \"Loss-of-heterozygosity/genomic deletion analysis; wild-type DR4 reconstitution by transfection; TRAIL cytotoxicity assays\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — natural deletion plus rescue experiment directly linking DR4 death domain loss to TRAIL resistance\",\n      \"pmids\": [\"10762627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DR4 undergoes constitutive clathrin-dependent and -independent endocytosis and recycling back to the plasma membrane independently of TRAIL sensitivity. Inhibition of endocytosis (with sucrose) sensitizes resistant cells to TRAIL and increases cytotoxicity in sensitive cells, indicating that endocytosis negatively regulates TRAIL-DR4 surface signaling.\",\n      \"method\": \"Live-cell flow cytometry tracking receptor internalization and recycling; receptor-selective TRAIL variant (DR5-B) to show DR5 internalizes independently of DR4; cycloheximide/brefeldin A to distinguish new synthesis from recycling; sucrose-mediated endocytosis inhibition with TRAIL cytotoxicity readout\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal pharmacological and biochemical approaches dissecting DR4 trafficking with functional death assay consequence\",\n      \"pmids\": [\"34660590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DR4 and DR5 redistribution into lipid rafts upon TRAIL treatment occurs in TRAIL-sensitive (H460) but not in TRAIL-resistant (A549) NSCLC cells; DR4 total expression level does not correlate with TRAIL sensitivity. Lipid raft disruption with nystatin abolishes sensitivity, and DR4 siRNA knockdown in sensitive cells does not affect TRAIL-induced apoptosis capacity, implicating that raft-localized DR4/DR5 rather than total DR4 expression drives sensitivity.\",\n      \"method\": \"Sucrose density gradient fractionation of lipid rafts; siRNA knockdown of DR4; nystatin treatment; TRAIL apoptosis assays\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — lipid raft fractionation plus siRNA in single lab, single study; negative DR4 siRNA result is informative\",\n      \"pmids\": [\"21769428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"DR4 and DR5 mediate oligomeric Aβ-induced extrinsic apoptosis in human cerebral microvascular endothelial cells: oligomeric Aβ directly binds DR4 and DR5 chimeric fusion proteins, upregulates their expression, and RNA silencing of both receptors protects against Aβ-induced caspase-8 and caspase-9 activation and Bid cleavage.\",\n      \"method\": \"Direct binding assay using receptor chimeras; RNA silencing of DR4 and DR5; caspase-8/9 activation assays; Bid cleavage assay; immunofluorescence co-localization\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ligand-binding assay and siRNA knockdown with multiple mechanistic readouts in single study\",\n      \"pmids\": [\"22695614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Valproic acid (a histone deacetylase inhibitor) causes redistribution of DR4 into plasma membrane lipid rafts in U266 myeloma cells, restoring DR4 signaling and overcoming TRAIL resistance; membrane expression level of DR4 (not total expression) and caspase-8 expression levels, but not Mcl-1 intracellular levels, predict myeloma cell sensitivity to TRAIL.\",\n      \"method\": \"Lipid raft fractionation; flow cytometry for membrane DR4; siRNA for caspase-8 and DR4/DR5; Mcl-1 overexpression; TRAIL apoptosis assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — lipid raft fractionation and multiple siRNA knockdowns in a single study establishing membrane DR4 as the functional determinant\",\n      \"pmids\": [\"17462628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Epigenetic silencing of DR4 via promoter hypermethylation underlies TRAIL resistance in ovarian cancer cells; demethylation with 5-aza-2'-deoxycytidine or transient DR4 transfection restores TRAIL sensitivity in the TRAIL-resistant A2780 cell line.\",\n      \"method\": \"Methylation-specific PCR; 5-aza-2'-deoxycytidine demethylation treatment; transient DR4 transfection; TRAIL apoptosis assays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — demethylation and DR4 reconstitution experiments with functional TRAIL sensitivity readout; single lab\",\n      \"pmids\": [\"15972852\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF10A/DR4 is a cell-surface death receptor that, upon binding of TRAIL/Apo2L, recruits FADD, TRADD, RIP1, and caspase-8 into a death-inducing signaling complex (DISC) to initiate caspase-8-dependent apoptosis; DR4 can also assemble a secondary complex with RIP1, TRAF2, and NEMO to activate NF-κB, JNK, and p38 kinase pathways. DR4 signaling competence is regulated post-translationally by S-palmitoylation (required for lipid raft localization and oligomerization) and N-linked glycosylation (promoting DISC assembly), as well as by S-nitrosylation at C336 (enhancing apoptotic signaling), and by intracellular trafficking controlled by the adaptor ARAP1. DR4 transcription is induced by DNA damage in a p53-dependent manner, and also activated by NF-κB (via MEKK1), by a DDIT3·phospho-JUN·KAT2A complex at its AP-1 promoter element, and repressed by the Hedgehog effector GLI3; promoter hypermethylation silences DR4 in some cancers to confer TRAIL resistance.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFRSF10A (DR4/TRAIL-R1) is a cell-surface death receptor that initiates extrinsic apoptosis upon engagement by TRAIL/Apo2L, and is the primary mediator of TRAIL-induced cell death in tumor cells [#13]. Through its cytoplasmic death domain, DR4 recruits the adaptor FADD (along with TRADD and RIP), assembling a death-inducing signaling complex in which FADD is an obligatory mediator of apoptosis [#0, #2, #14]. Ligand engagement also nucleates a secondary complex retaining FADD and caspase-8 but additionally recruiting RIP1, TRAF2, and NEMO/IKK\\u03b3, thereby activating IKK/NF-\\u03baB, JNK, and p38 kinase pathways [#4]. DR4-driven caspase-8 activity cleaves BID to engage mitochondrial BAX, linking the receptor to the intrinsic apoptotic machinery during p53-driven genotoxic stress responses [#11]. DR4 signaling competence is set post-translationally: S-palmitoylation of its cytoplasmic domain drives lipid-raft localization and oligomerization [#5], N-linked glycosylation promotes receptor aggregation and DISC formation [#12], and S-nitrosylation at C336 enhances caspase-8 activation [#6]; surface availability is further governed by ARAP1-dependent trafficking to the plasma membrane [#8] and by constitutive endocytosis and recycling that negatively regulate surface signaling [#15]. DR4 transcription is induced by DNA damage in a p53-dependent manner [#3], by NF-\\u03baB/p65 via MEKK1 [#7], and by a KAT2A\\u00b7DDIT3\\u00b7phospho-JUN complex acting at an AP-1 promoter element during ER stress [#9], while it is repressed by the Hedgehog effector GLI3 and silenced by promoter hypermethylation to confer TRAIL resistance in cancer [#10, #19].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established the core proximal signaling machinery of DR4 by identifying the death-domain adaptors that transduce its apoptotic and NF-\\u03baB signals.\",\n      \"evidence\": \"Co-IP of FADD/TRADD/RIP with DR4 and dominant-negative FADD blocking apoptosis; NF-\\u03baB reporter assays\",\n      \"pmids\": [\"9430227\", \"9430228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and order of adaptor assembly not resolved\", \"Did not distinguish DISC from secondary complex\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Raised the possibility that TRAIL signals through mixed receptor complexes by showing DR4 can associate with DR5.\",\n      \"evidence\": \"Co-IP of TRAIL-R1 with TRAIL-R2\",\n      \"pmids\": [\"9430228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP without reciprocal independent validation\", \"Functional significance of heterocomplex unproven\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Confirmed FADD as an obligatory component of DR4 apoptosis using a clean cellular loss-of-function approach.\",\n      \"evidence\": \"Stable dominant-negative GFP-FADD expression in HeLa cells with cell death assays\",\n      \"pmids\": [\"9427646\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dominant-negative may affect other death receptors\", \"Did not address downstream caspase cascade specifics\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrated that the DR4 death domain is genetically required for TRAIL-induced apoptosis via a natural deletion and rescue.\",\n      \"evidence\": \"Genomic deletion analysis in FaDu cells plus wild-type DR4 reconstitution and TRAIL cytotoxicity\",\n      \"pmids\": [\"10762627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single cell-line context\", \"Does not separate DR4 contribution from DR5 in other settings\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Placed DR4 in the DNA-damage response by establishing it as a p53-inducible gene, connecting genotoxic stress to extrinsic apoptosis.\",\n      \"evidence\": \"RT-PCR/Western in irradiated and drug-treated cells with adenoviral p53 gain- and HPV E6 loss-of-function\",\n      \"pmids\": [\"11382926\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct p53 binding site not mapped here\", \"Whether induction is sufficient for apoptosis not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified promoter hypermethylation as an epigenetic mechanism that silences DR4 and confers TRAIL resistance.\",\n      \"evidence\": \"Methylation-specific PCR, 5-aza-2'-deoxycytidine demethylation, and DR4 reconstitution in ovarian cancer cells\",\n      \"pmids\": [\"15972852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab/cell line\", \"Demethylation effects not gene-specific\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined how DR4 activates kinase pathways by resolving a secondary signaling complex distinct from the DISC.\",\n      \"evidence\": \"Co-IP of secondary complex, siRNA of RIP1/TRAF2/NEMO, dominant-negatives, and kinase assays\",\n      \"pmids\": [\"16227629\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial/temporal relationship to primary DISC not fully resolved\", \"Physiological outcome of NF-\\u03baB/JNK/p38 activation context-dependent\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed S-palmitoylation as a DR4-specific lipid modification required for raft localization and oligomerization, distinguishing it from DR5 and TNFR1.\",\n      \"evidence\": \"Palmitoylation assay, raft fractionation, oligomerization assays, comparison with DR5/TNFR1\",\n      \"pmids\": [\"19090789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Palmitoyltransferase responsible not identified\", \"Dynamics/reversibility of palmitoylation unaddressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified C336 S-nitrosylation as a functionally critical redox modification enhancing DR4 death signaling.\",\n      \"evidence\": \"Biotin-switch assay, systematic mutagenesis of all cytoplasmic cysteines, caspase-8 and viability assays\",\n      \"pmids\": [\"16847314\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous NO source/enzyme not defined\", \"Structural basis of how nitrosylation enhances signaling unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed direct NF-\\u03baB/p65 transcriptional control of DR4 downstream of MEKK1, adding a second stress-responsive induction route.\",\n      \"evidence\": \"Promoter reporter with site mutation, EMSA, ChIP, p65 RNAi, kinase-inactive MEKK1\",\n      \"pmids\": [\"18421578\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crosstalk with p53-driven induction not resolved\", \"Conditions favoring NF-\\u03baB vs p53 control unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified ARAP1 as a trafficking adaptor controlling DR4 delivery to the cell surface, linking receptor abundance at the membrane to apoptotic competence.\",\n      \"evidence\": \"Yeast two-hybrid with DR4-ICP, Co-IP, confocal co-localization, siRNA with flow cytometry and death assays\",\n      \"pmids\": [\"18165900\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GAP catalytic role in trafficking not dissected\", \"Direct vs indirect interaction not fully established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated Hedgehog-mediated repression of DR4 through GLI3 binding, explaining a transcriptional route to TRAIL resistance.\",\n      \"evidence\": \"Promoter reporter, ChIP, GLI1/2/3 and DR4 siRNA, death assays in cholangiocarcinoma\",\n      \"pmids\": [\"20562908\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"GLI3 repressor cofactors not identified\", \"Generality beyond cholangiocarcinoma untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed that raft-localized rather than total DR4 determines TRAIL sensitivity, refining the receptor-availability model.\",\n      \"evidence\": \"Sucrose-gradient raft fractionation, DR4 siRNA, nystatin disruption, apoptosis assays in NSCLC lines\",\n      \"pmids\": [\"21769428\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-study two-cell-line comparison\", \"Molecular trigger of raft redistribution not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed DR4 mechanistically within the p53 apoptosis decision, upstream of caspase-8/BID/BAX, linking extrinsic and intrinsic pathways.\",\n      \"evidence\": \"Isogenic epistasis, DR4 siRNA, caspase-8 inhibition, BID cleavage and cytochrome C release assays\",\n      \"pmids\": [\"22246181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of DR4 vs DR5 in p53 response not separated\", \"Determinants of apoptosis vs arrest choice partly unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended DR4 ligand biology beyond TRAIL by showing oligomeric A\\u03b2 binds DR4 to drive endothelial apoptosis.\",\n      \"evidence\": \"Receptor chimera binding, DR4/DR5 RNA silencing, caspase-8/9 and Bid cleavage assays\",\n      \"pmids\": [\"22695614\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-study system (cerebral endothelial cells)\", \"Physiological relevance and binding site not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined an ER-stress transcriptional module (KAT2A\\u00b7DDIT3\\u00b7phospho-JUN) that activates DR4 via histone acetylation at an AP-1 promoter element.\",\n      \"evidence\": \"Co-IP, ChIP, AP-1 site reporter mutagenesis, KAT2A siRNA, H3K9/K14 acetylation Western\",\n      \"pmids\": [\"25770212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Integration with NF-\\u03baB and p53 inputs unresolved\", \"Stimulus specificity of complex assembly unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established DR4 as the primary TRAIL apoptosis mediator and a participant in ER-stress apoptosis, while distinguishing it from DR5 in being unable to drive migratory calcium signaling.\",\n      \"evidence\": \"TALEN-edited isogenic DR4/DR5 knockouts, Co-IP with FADD/caspase-8 under ER stress, calcium flux and motility assays\",\n      \"pmids\": [\"28039489\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism for DR4's inability to flux calcium not defined\", \"Cell-line dependence of receptor dominance\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed N-linked glycosylation promotes DR4 aggregation and DISC formation and modulates viral immune evasion, defining a glycan-level control of signaling.\",\n      \"evidence\": \"Glycosylation-site mutagenesis, DISC IP, TRAIL- and UL141-binding assays, apoptosis readouts\",\n      \"pmids\": [\"28186505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific glycan structures involved not characterized\", \"In vivo relevance of UL141 modulation untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated that constitutive endocytosis and recycling of DR4 negatively regulate surface TRAIL signaling, providing a dynamic control of receptor availability.\",\n      \"evidence\": \"Live-cell flow cytometry of internalization/recycling, receptor-selective TRAIL variant, brefeldin A/cycloheximide, sucrose endocytosis inhibition with cytotoxicity\",\n      \"pmids\": [\"34660590\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Adaptors/machinery selecting clathrin-dependent vs independent routes unidentified\", \"Signaling status of internalized receptor unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple post-translational modifications, trafficking routes, and competing transcriptional inputs are integrated to set DR4 surface density and signaling competence in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking palmitoylation, glycosylation, nitrosylation, ARAP1 trafficking, and endocytosis\", \"Enzymes catalyzing palmitoylation and physiological NO-donor unknown\", \"Hierarchy of p53, NF-\\u03baB, DDIT3/AP-1, and GLI3 transcriptional control not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 13, 14]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 8, 15, 16]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [8, 15]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 2, 11, 13, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [9, 13]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 7, 9, 10]}\n    ],\n    \"complexes\": [\"DISC (death-inducing signaling complex)\", \"TRAIL secondary signaling complex (FADD/caspase-8/RIP1/TRAF2/NEMO)\", \"KAT2A\\u00b7DDIT3\\u00b7phospho-JUN promoter complex\"],\n    \"partners\": [\"FADD\", \"TRADD\", \"RIP1\", \"TRAF2\", \"NEMO\", \"TNFRSF10B\", \"ARAP1\", \"CASP8\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}